Botulinum toxin injections are becoming a major therapeutic option for neurological disorders not only of muscle hyperactivities but also of pain and other conditions. This workshop aims at delivering pearls of various aspects of its clinical uses form the experts. The content will be understandable for beginners, but many experienced neurologists can still learn from this unique opportunity of the virtual workshop.

Envisioning a more inclusive, diverse and equitable global migraine landscape: are we making progress? During this symposium, we will consider the myriad social determinants of health in general and – focusing on migraine specifically – critique the current state of diversity in clinical studies. We will also review what the latest data tell us about the efficacy and tolerability of monoclonal antibodies targeting the calcitonin gene-related peptide pathway (CGRP mAbs) for migraine prevention across diverse patient subgroups, including different ethnicities, migraine characteristics and comorbidities. We hope you will join us as we attempt to address this important question: are we making progress towards a more inclusive, diverse, and equitable global migraine landscape?

This session consists of two topics as follow: • 14:00 - 14:30 - Immune response to SARS-CoV2 infection and vaccination: what have we learnt from patients in treatment with ocrelizumab, chaired by Claudio Gasperini The recent SARS-COV-2 pandemic has caused a global challenge in the field of MS with a review of the management of current and planned therapies. To date, the literature has allowed us to clarify that, generally, therapies for MS do not seem to increase the risk of contracting COVID-19 or developing a severe form and that there are other predisposing factors such as age, comorbidities, etc. . The world of neurology, however, still has many open questions and needs answers and comparison with the leading experts in immunology to better manage the therapeutic approach towards the available vaccination platforms. The response to vaccination cannot only be based on an assessment of the antibody response but must rather also take into account the cellular response T mediated considering a long-term safety issue. • 14:30 – 15:30 - Our journey in MS: from current paradigms to future scientific advances, chaired by Massimo Filippi MS is a chronic disabling disease that requires the patient to undertake a long and complex socio-assistance path. In spite of the wide spectrum of therapeutic opportunities, several MS patients even without clinical or radiological disease activity, despite having a form of relapsing remitting at the beginning, present at some point a worsening linked to a progression that appears to be present from the very first phases of the disease, completely independent from relapse or in any case from the disease activity, even if only radiological. Hence the need for the clinician to adopt clinical, radiological and biohumoral tools (often not yet of routine use) useful for intercepting this delicate phase of the disease in clinical practice. It is important to analyze all the latest scientific evidence in order to promote diagnostic protocols that can be useful in facilitating the recognition and consequently also the management of patients who are in this phase of the disease.

Recognize, Treat & Follow: Reimagining the Patient Journey Following Gene Therapy Join us on Tuesday 5 October 2021, 14:00 – 15:30 CET for this Novartis Gene Therapies-sponsored virtual symposium entitled: ‘Recognize, Treat & Follow: Reimagining the Patient Journey Following Gene Therapy’ where you will have the opportunity to learn about the emerging role of gene therapy (GT) for neurological disorders, and the importance of early diagnosis and treatment in the spinal muscular atrophy (SMA) therapeutic landscape. During this symposium, our faculty of experts aim to present growing clinical and real-world evidence of efficacy and safety following GT for patients with SMA. We also hope to capture the multidisciplinary team and patient perspectives on the SMA treatment journey and transition into adulthood after GT administration. To finish the program, our experts will participate in a panel discussion and live question and answer session. We look forward to welcoming you for what promises to be an informative and engaging virtual event.